# Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

Study · id `cardio:ct-nct07405216` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07405216](<https://clinicaltrials.gov/study/NCT07405216>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07405216

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT07405216. Randomized; triple masking; primary purpose treatment. Start 2026-04-23 (actual); primary completion 2027-05-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT07405216, source copy `cardio:ctgov-nct07405216-2026-04-27`, retrieved 2026-10-26)
- Started: 2026-04-23 (actual) (ClinicalTrials.gov record NCT07405216, source copy `cardio:ctgov-nct07405216-2026-04-27`, retrieved 2026-10-26)
- Primary completion: 2027-05-30 (anticipated) (ClinicalTrials.gov record NCT07405216, source copy `cardio:ctgov-nct07405216-2026-04-27`, retrieved 2026-10-26)
- Completion: 2027-10-30 (anticipated) (ClinicalTrials.gov record NCT07405216, source copy `cardio:ctgov-nct07405216-2026-04-27`, retrieved 2026-10-26)
- Countries: Mexico (ClinicalTrials.gov record NCT07405216, source copy `cardio:ctgov-nct07405216-2026-04-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07405216-2026-04-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease
- Acronym: IECA-MEX
- Condition: Chronic Kidney Disease (Mild to Moderate)
- Condition: Albuminuria
- Condition: Adolescent
- Condition: Sodium Glucose Co-Transporter 2 Inhibitors
- Intervention (Drug): Dapagliflozin (10mg Tab)
- Intervention (Drug): Placebo
- Lead sponsor: Centenario Hospital Miguel Hidalgo
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)

## Provenance

Content hash: f1a15769bc30c9c109a6538b40011f8da14aa4fa0505efcff6d5feb39c1d894c
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
